Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Payables: 2016-2024

Historic Payables for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $15.2 million.

  • Akebia Therapeutics' Payables fell 25.25% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.5 million, marking a year-over-year decrease of 1.27%. This contributed to the annual value of $15.2 million for FY2024, which is 3.72% up from last year.
  • Latest data reveals that Akebia Therapeutics reported Payables of $15.2 million as of FY2024, which was up 3.72% from $14.6 million recorded in FY2023.
  • Akebia Therapeutics' 5-year Payables high stood at $41.3 million for FY2020, and its period low was $14.6 million during FY2023.
  • Moreover, its 3-year median value for Payables was $15.2 million (2024), whereas its average is $15.9 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Payables increased by 5.33% in 2020, and later tumbled by 46.35% in 2022.
  • Over the past 5 years, Akebia Therapeutics' Payables (MRY) stood at $41.3 million in 2020, then fell by 18.69% to $33.6 million in 2021, then plummeted by 46.35% to $18.0 million in 2022, then fell by 18.79% to $14.6 million in 2023, then rose by 3.72% to $15.2 million in 2024.
  • Its last three reported values are $15.2 million in FY2024, $14.6 million for FY2023, and $18.0 million during FY2022.